Firehawk® Gains Launch Approval in Hong Kong Public Hospitals
Hong Kong, China – On May 21, Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") gained the approval from Hong Kong Hospital Authority, allowing it to enter in Hong Kong public hospitals. It is the first drug-eluting stent of MicroPort® that was granted launch approval in Hong Kong.
Firehawk® is the result of eight years of research and development of MicroPort® and it is the world's first and only target-eluting stent ("TES"). It is a new-generation drug-eluting stent of MicroPort® for the treatment of coronary artery stenosis or occlusion after Firebird® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird®") and Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®"). Firehawk® adopts TES Technology platform, and its coating area is only 20% of the stent surface. Firehawk®'s drug is released over 90 days and its polymer is fully absorbed in nine months. Its average metal coverage rate is 14.0-16.1%. Firehawk® is the world's lowest drug dosage stent, with only 1/3 dosage versus similar products while achieving the same efficacy.
Firehawk®'s Hong Kong launch marks a milestone in its market development. With its outstanding performance, it is expected that Firehawk® will provide more ideal cardiovascular treatment for local patients and help enhance the communication between cardiologists from Hong Kong and the mainland as well.
Privacy settings
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.
For more information, please see our Cookie Policy.